Merck of Germany has signed a deal for the development of an experimental cancer drug from the Beijing-based biotech company BeiGene, in the latest sign of expansion of the fledgling life science sector in China.
The contract, for a drug called BeiGene-290, is the second agreed this year by Merck with BeiGene. It expands a partnership to cover the Chinese company’s two most advanced, locally developed oncology treatments.
The agreement comes at a time of intensifying links between multinational pharmaceutical companies and nascent Chinese drug developers following substantial government investment in medical research and the return of many experienced drug company scientists from the US.
您已阅读51%（694字），剩余49%（654字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。